Login to Your Account



Financing Roundup

NitroMed, Preparing For BiDil Launch, Publicly Raises $80M

By Karen Pihl-Carey


Thursday, December 9, 2004
Positive Phase III results for its heart failure drug BiDil certainly played a role in NitroMed Inc.'s ability to raise almost $80 million in a public offering on Wednesday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription